Macrophage colony stimulating factor receptor antagonists - Pipeline Insight, 2022
This report can be delivered to the clients within 3-4 Business Days
DelveInsight’s, “Macrophage colony stimulating factor receptor antagonists - Pipeline Insight, 2022” report provides comprehensive insights about 18+ companies and 18+ pipeline drugs in Macrophage colony stimulating factor receptor antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Macrophage colony stimulating factor receptor antagonists: Overview
Macrophage-colony stimulating factor (CSF-1) signaling through its receptor (CSF-1R) promotes the differentiation of myeloid progenitors into heterogeneous populations of monocytes, macrophages, dendritic cells, and bone-resorbing osteoclasts. In the periphery, CSF-1 regulates the migration, proliferation, function, and survival of macrophages, which function at multiple levels within the innate and adaptive immune systems. Macrophage populations elicited by CSF-1 are associated with, and exacerbate, a broad spectrum of pathologies, including cancer, inflammation, and bone disease. Conversely, macrophages can also contribute to immunosuppression, disease resolution, and tissue repair. Macrophage colony-stimulating factor. Inhibition of macrophage-colony stimulating factor reduces immune cell infiltration and inflammation in the EAE model that mimics the massive invasion of systemic immune cells in the CNS. In the same line, macrophage-colony stimulating factor deficiency prevents tumor invasion in glioblastoma.
Report Highlights
This segment of the Macrophage colony stimulating factor receptor antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Macrophage colony stimulating factor receptor antagonists Emerging Drugs
Further product details are provided in the report……..
Macrophage colony stimulating factor receptor antagonists: Therapeutic Assessment
This segment of the report provides insights about the different Macrophage colony stimulating factor receptor antagonists drugs segregated based on following parameters that define the scope of the report, such as:
Macrophage colony stimulating factor receptor antagonists: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Macrophage colony stimulating factor receptor antagonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Macrophage colony stimulating factor receptor antagonists drugs.
Macrophage colony stimulating factor receptor antagonists Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Macrophage colony stimulating factor receptor antagonists - Pipeline Insight, 2022” report provides comprehensive insights about 18+ companies and 18+ pipeline drugs in Macrophage colony stimulating factor receptor antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Macrophage colony stimulating factor receptor antagonists: Overview
Macrophage-colony stimulating factor (CSF-1) signaling through its receptor (CSF-1R) promotes the differentiation of myeloid progenitors into heterogeneous populations of monocytes, macrophages, dendritic cells, and bone-resorbing osteoclasts. In the periphery, CSF-1 regulates the migration, proliferation, function, and survival of macrophages, which function at multiple levels within the innate and adaptive immune systems. Macrophage populations elicited by CSF-1 are associated with, and exacerbate, a broad spectrum of pathologies, including cancer, inflammation, and bone disease. Conversely, macrophages can also contribute to immunosuppression, disease resolution, and tissue repair. Macrophage colony-stimulating factor. Inhibition of macrophage-colony stimulating factor reduces immune cell infiltration and inflammation in the EAE model that mimics the massive invasion of systemic immune cells in the CNS. In the same line, macrophage-colony stimulating factor deficiency prevents tumor invasion in glioblastoma.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Macrophage colony stimulating factor receptor antagonists R&D. The therapies under development are focused on novel approaches for Macrophage colony stimulating factor receptor antagonists.
This segment of the Macrophage colony stimulating factor receptor antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Macrophage colony stimulating factor receptor antagonists Emerging Drugs
- Pacritinib: CTI BioPharma
- AMB 051: AmMax Bio
Further product details are provided in the report……..
Macrophage colony stimulating factor receptor antagonists: Therapeutic Assessment
This segment of the report provides insights about the different Macrophage colony stimulating factor receptor antagonists drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Macrophage colony stimulating factor receptor antagonists
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Macrophage colony stimulating factor receptor antagonists: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Macrophage colony stimulating factor receptor antagonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Macrophage colony stimulating factor receptor antagonists drugs.
Macrophage colony stimulating factor receptor antagonists Report Insights
- Macrophage colony stimulating factor receptor antagonists Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Macrophage colony stimulating factor receptor antagonists drugs?
- How many Macrophage colony stimulating factor receptor antagonists drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Macrophage colony stimulating factor receptor antagonists?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Macrophage colony stimulating factor receptor antagonists therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Macrophage colony stimulating factor receptor antagonists and their status?
- What are the key designations that have been granted to the emerging drugs?
- CTI BioPharma
- AmMax Bio
- Novartis
- Plexxikon
- Daiichi Sankyo Company
- Basilea Pharmaceutica
- Turning Point Therapeutics
- HUTCMED
- Elixiron Immunotherapeutics
- BCI Pharma
- SignalChem Lifesciences
- Eli Lilly and Company
- Nerviano Medical Sciences
- Roche
- Qurient Co
- Chipscreen Biosciences
- Abbisko Therapeutics
- Janssen Research & Development
- Bristol-Myers Squibb
- Syndax Pharmaceuticals
- Pacritinib
- AMB 051
- BLZ 945
- Cabiralizumab
- PLX-3397
- Quizartinib
- Axatilimab
- PLX4720
- Edicotinib
- ABSK 021
- Chiauranib
- Derazantinib
- NMS 03592088
- Q 702
- Emactuzumab
- Elzovantinib
- Surufatinib
- EI 003
- EI 1071
- BCI 1415
- IMC CS4
Introduction
Executive Summary
Macrophage colony stimulating factor receptor antagonists: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Macrophage colony stimulating factor receptor antagonists – DelveInsight’s Analytical Perspective
Late Stage Products (Preregistration)
Comparative Analysis
Pacritinib: CTI BioPharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
AMB 051: AmMax Bio
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
EI 1071: Elixiron Immunotherapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
BCI 1415: BCI Pharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Macrophage colony stimulating factor receptor antagonists Key Companies
Macrophage colony stimulating factor receptor antagonists Key Products
Macrophage colony stimulating factor receptor antagonists- Unmet Needs
Macrophage colony stimulating factor receptor antagonists- Market Drivers and Barriers
Macrophage colony stimulating factor receptor antagonists- Future Perspectives and Conclusion
Macrophage colony stimulating factor receptor antagonists Analyst Views
Macrophage colony stimulating factor receptor antagonists Key Companies
Appendix
Executive Summary
Macrophage colony stimulating factor receptor antagonists: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Macrophage colony stimulating factor receptor antagonists – DelveInsight’s Analytical Perspective
Late Stage Products (Preregistration)
Comparative Analysis
Pacritinib: CTI BioPharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
AMB 051: AmMax Bio
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
EI 1071: Elixiron Immunotherapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
BCI 1415: BCI Pharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Macrophage colony stimulating factor receptor antagonists Key Companies
Macrophage colony stimulating factor receptor antagonists Key Products
Macrophage colony stimulating factor receptor antagonists- Unmet Needs
Macrophage colony stimulating factor receptor antagonists- Market Drivers and Barriers
Macrophage colony stimulating factor receptor antagonists- Future Perspectives and Conclusion
Macrophage colony stimulating factor receptor antagonists Analyst Views
Macrophage colony stimulating factor receptor antagonists Key Companies
Appendix